Ask AI
ProCE Banner Activity

The APP Advantage: Optimizing BCMA- and GPRC5D-Directed Bispecific Antibody Care in Multiple Myeloma

Slideset

Download slides from a live webinar to gain expert perspectives on the role of APPs in managing patients with multiple myeloma receiving bispecific antibody therapy.

Released: September 18, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for nurse practitioners, physician assistants/physician associates, nurses, clinical nurse specialists, and other healthcare professionals who care for patients with multiple myeloma in community oncology and hematology practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate approved and emerging BCMA- and GPRC5D-directed bispecific antibody strategies for relapsed/refractory multiple myeloma using target, line of therapy, prior treatment exposure, administration route, dosing schedule, monitoring requirements, and toxicity profile

  • Apply guideline- and REMS-aligned strategies to prevent, identify, and manage bispecific antibody–associated CRS, ICANS, cytopenias, infections, hypogammaglobulinemia, and GPRC5D-associated oral, dermatologic, nail, taste, and nutrition-related toxicities

  • Implement an APP-led care-coordination pathway for bispecific antibody initiation, step-up dosing and monitoring, delayed-dose or restart scenarios, emergency department handoffs, and longitudinal community follow-up

  • Use shared decision-making and teach-back counseling to help patients and caregivers understand expected benefits, monitoring requirements, toxicity reporting, infection prevention, and access-related barriers to bispecific antibody therapy